Company · ONC
BeOne Medicines (BeiGene)
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
6
5 still marketed
Novel approvals
3
Approvals since 2021
21
Originals and new uses
Phase 3 trials
37
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Tevimbra new use Priority reviewOrphanAug 25, 2026
- Beqalzi approved NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 13, 2026
- Tevimbra new use OrphanDec 9, 2025
- Tevimbra new use OrphanDec 9, 2025
- Tevimbra new use OrphanDec 9, 2025
- Brukinsa approved Accelerated approvalOrphanJun 10, 2025
- Brukinsa approved OrphanJun 10, 2025
- Tevimbra new use OrphanApr 22, 2025
- Tevimbra new use OrphanApr 22, 2025
- Tevimbra new use OrphanApr 22, 2025
Drugs in development (12)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- TacabrutidegBGB-16673Phase 36 trials
BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma
- GimistotugBGB-A445Phase 34 trials
BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma
- BGB-15025Phase 33 trials
BeOne Medicines (BeiGene) · Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Advanced Malignancies
- BGB-B2033Phase 33 trials
BeOne Medicines (BeiGene) · Liver Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer
- FluoropyrimidinePhase 33 trials
Seattle Project Corporation · Colorectal Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma, Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- SurzebiclimabBGB-A425Phase 33 trials
BeOne Medicines (BeiGene) · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- OciperlimabBGB-A1217Phase 32 trials
BeOne Medicines (BeiGene) · Non Small Cell Lung Cancer, Advanced Malignancies
- PamiparibBGB-290Phase 32 trials
BeOne Medicines (BeiGene) · Ovarian Cancer, Advanced Malignancies
- SitravatinibMGCD516Phase 32 trials
BeOne Medicines (BeiGene) · Advanced Malignancies, Advanced or Metastatic Solid Malignancies
- BAT1706Phase 31 trial
BeOne Medicines (BeiGene) · Advanced Malignancies
- BGB-43395Phase 31 trial
BeOne Medicines (BeiGene) · HR+/HER2- Breast Cancer
Recruiting Phase 3 trials
Largest first.
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseasePivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07492641 · 1,056 participants (planned) · Start May 22, 2026 · Primary completion Apr 2029
Drug: BGB-43395; Letrozole and 3 more · For: HR+/HER2- Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 241 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06943872 · 630 participants (planned) · Start Jun 11, 2025 · Primary completion Sep 30, 2029
Drug: Sonrotoclax; Obinutuzumab and 2 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Laguna Hills, California; Orange, California; Palo Alto, California · 195 sites in all
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaPivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07277231 · 500 participants (planned) · Start Jan 22, 2026 · Primary completion Feb 2031
Drug: Sonrotoclax; Zanubrutinib and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Duarte, California; Orange, California; Palo Alto, California · 115 sites in all
- A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06973187 · 500 participants (planned) · Start Sep 4, 2025 · Primary completion Apr 17, 2028
Drug: Tacabrutideg; Pirtobrutinib · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Irvine, California · 217 sites in all
- Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular CarcinomaPivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07836530 · 492 participants (planned) · Start Oct 23, 2026 · Primary completion Sep 21, 2029
Drug: BGB-B2033; Lenvatinib and 1 more · For: Hepatocellular Carcinoma; Liver Cancer
Sites: South Brisbane, Australia; Grafton, New Zealand
- A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaPivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07043400 · 351 participants (planned) · Start Aug 27, 2025 · Primary completion Oct 30, 2027
Drug: Subcutaneous Tislelizumab; Intravenous Tislelizumab and 5 more · For: Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
Sites: Chandler, Arizona; Los Alamitos, California; Colorado Springs, Colorado · 95 sites in all
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)Pivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06742996 · 300 participants (planned) · Start Mar 5, 2025 · Primary completion Aug 31, 2028
Drug: Sonrotoclax; Zanubrutinib and 1 more · For: Mantle Cell Lymphoma; B Cell Lymphoma
Sites: Birmingham, Alabama; Tucson, Arizona; Fresno, California · 145 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06846671 · 250 participants (planned) · Start Apr 10, 2025 · Primary completion May 15, 2028
Drug: Tacabrutideg; Bendamustine and 3 more · For: CLL; Chronic Lymphocytic Leukemia; SLL
Sites: Jonesboro, Arkansas; Los Angeles, California; San Diego, California · 134 sites in all
Marketed drugs (5)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.